After GlucoTrack, Inc. (NASDAQ: GCTK) released encouraging results from its first-in-human clinical research, the company’s shares surged 26.25% to $7.84 during the previous session. The results were presented last week in Chicago at the American Diabetes Association’s (ADA) 85th Scientific Sessions.
Implantable Blood-Based Glucose Monitor Validated by Study
With GlucoTrack’s implanted Continuous Blood Glucose Monitor (CBGM) attaining a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs and a 99% data collection rate, the clinical research achieved all primary and secondary goals. Crucially, there were no documented severe adverse effects connected to the surgery or the gadget.
The GlucoTrack device eliminates lag periods and improves real-time accuracy by measuring glucose directly from blood rather than interstitial fluid, in contrast to typical CGMs. On June 21, these findings were presented in front of a packed Innovation Hub at the ADA event.
AI-Driven Analysis Confirms High Accuracy
GlucoTrack collaborated with OneTwo Analytics to utilize artificial intelligence and machine learning tools for data evaluation. Ninety-two percent of readings were in the green (safe) zone, with none falling into clinically dangerous areas, according to the Diabetes Technology Society’s Error Grid study. This demonstrates how accurate the equipment is in comparison to conventional blood glucose testing.
Effective Trial Conduct and Upcoming Actions
Ten individuals with Type 1 or Type 2 diabetes receiving intense insulin therapy participated in the trial, which was conducted at the Instituto do Coração in São Paulo, Brazil, between December 2024 and January 2025. Interventional cardiologists used normal percutaneous techniques to implant and remove devices.
Participants were observed for four days in an inpatient setting, where continuous blood sampling and glucose tolerance tests revealed consistent performance with minimal lag time. Following a seven-day post-removal observation, the devices were successfully retrieved at the conclusion of the trial and remained operational throughout.
In light of these encouraging findings, GlucoTrack is getting ready to start a long-term early feasibility study in Q3 2025 in order to confirm the device’s long-term safety and effectiveness and take another step toward revolutionizing continuous glucose monitoring.
